Video

Dr. Zamarin on the Role of Vaccines in Cervical Cancer

Author(s):

Dmitriy Zamarin, MD, PhD

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of vaccines for patients with cervical cancer.

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of vaccines for patients with cervical cancer.

Cervical cancer presents itself as a good candidate for a vaccine-type of therapy because the majority of tumors are HPV-driven, explains Zamarin.

There are several vaccines that have been demonstrated to elicit specific immune responses. There is a vaccine from Inovio called VGX-3100 that was effective in the precancerous setting in patients with CIN 2/3, states Zamarin. This could then be effective in advanced settings.

Related Videos
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie
Breelyn Wilky, director, Sarcoma Medical Oncology, The Cheryl Bennett and McNeilly Family Endowed Chair in Sarcoma Research, deputy associate director, Clinical Research, associate professor, medicine, medical oncology, the University of Colorado Medicine
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Kimberly Cannavale, MPH
Rahul Banerjee, MD, FACP
Grzegorz S. Nowakowski, MD
Katharine A. Price, MD
Richard Kim, MD
Alexey Danilov, MD, PhD
Related Content
Toon Van Gorp, MD, a gynecologist oncologist in the Department of Gynecology and Obstetrics at UZ Leuven
September 14th 2024

Adjuvant Pembrolizumab/Chemotherapy Misses DFS End Point in High-Risk Endometrial Cancer, but Benefits dMMR Subgroup

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

OncLive’s August Roundup of Key FDA Approvals in Oncology
September 4th 2024

OncLive’s August Roundup of Key FDA Approvals in Oncology

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Revisit Every OncLive On Air Episode From August 2024
August 30th 2024

Revisit Every OncLive On Air Episode From August 2024

Ritu Salani, MD, director, Gynecologic Oncology, University of California Los Angeles
August 28th 2024

Novel Targets Facilitate Treatment Advances and Spur Further Questions in Endometrial Cancer